Importantly, combining the epigenetic anti‐tumor drug GSK3326595 with CPT‐11 significantly upregulates the immune receptor tyrosine‐based inhibitory motif (TIGIT) level on CD8+ T cells and subsequently demonstrates impressive anti‐tumor efficacy in vivo when additional anti‐TIGIT is included. This evidence concerns the gene CD8A and neoplasm.